Sep 2026
Abstract B008: Pan-RAS-GTP inhibition disrupts the KRAS-SHH axis to reprogram cancer-associated fibroblast subtypes and reduce stiffness in pancreatic cancer
Oncogenic KRAS mutations are present in ∼95% of pancreatic ductal adenocarcinoma (PDAC) cases and have long been considered undruggable. The recent clinical emergence of RAS inhibitors marks a transformative moment in PDAC therapy, yet their impact on the tumor microenvironment (TME) remains largely unknown. This is...
Marie C. Hasselluhn, Allison C. Hess, L. Tomassoni et al.
· Cancer Research · 0 citations